The aims of this study were to investigate various factors associated with protective anti-rabies antibody status (0.5 EU/ml) in vaccinated pet dogs and anti-rabies antibody status in unvaccinated stray dogs. One hundred and seven serum samples were collected from vaccinated pet dogs, out of these 58 (62.36 %) dogs showed antibody titre above 0.5 EU/ml. All the dogs were divided into different groups based on age, sex, breed, vaccine brand and time of vaccination after last vaccine to assess the relationship of these factors with vaccinal immune response. One way analysis of variance was performed in graphpad prism software to check the effect of all these factors. Statistical analysis of ELISA titres of pet dog serum samples suggested that age, sex, breed and vaccine brands have no significant effect on the anti-rabies antibody titres. To check anti-rabies antibody status in stray dogs 53 serum samples were collected and only one out of 53 (1.88 %) stray dogs showed anti-rabies antibody titre above 0.5 EU/ml indicating susceptibility to rabies infection and thereby posing possible threat to surrounding human and animal populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663715 | PMC |
| http://dx.doi.org/10.1007/s13337-015-0284-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-16 exerts anti-rabies virus effects through CD9 on the surface of viral particles.
Int J Biol Macromol
February 2025
Research Center of Molecular Medicine of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, PR China. Electronic address:
Rabies, caused by the rabies virus (RABV; scientific name Rabies lyssavirus), is invariably fatal, and currently, there is no specific drug for its treatment. Previous studies have demonstrated the relationship between CD9 and the RABV. However, it remains unclear whether CD9 and IL-16 affect the RABV life cycle.
View Article and Find Full Text PDFA prospective study on safety and clinical efficacy of rabies biologicals in paediatric patients with category III animal exposure.
Clin Exp Vaccine Res
January 2025
Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India.
Purpose: Rabies remains a significant public health concern worldwide, particularly among paediatric populations who are vulnerable to animal exposures. This prospective study aimed to assess the safety and clinical efficacy of rabies biologicals in pediatric patients following category III animal exposures.
Materials And Methods: A prospective study was undertaken enrolling 289 pediatric patients fulfilling eligibility criteria who presented with category III animal exposures at the anti-rabies clinic of Kempegowda Institute of Medical Sciences Hospital and Research Centre, Bangalore.
Safety Evaluation of the Novel Cocktail of Monoclonal Antibodies for Postexposure Prophylaxis in Category III Animal Exposures.
J Glob Infect Dis
October 2024
Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India.
Introduction: Rabies monoclonal antibody (mAb) is a life-saving immune-biological for postexposure prophylaxis (PEP) in all Category III animal exposures. A novel cocktail of mAbs derived using recombinant DNA technology is presently available for usage. The WHO recommends monitoring the clinical use and outcomes of mAb products.
View Article and Find Full Text PDFCellular immune response against rabies vaccination in laboratory-bred dogs: A systematised review.
Lab Anim
January 2025
Department of Physiology, Faculty of Medicine, University of Colombo, Sri Lanka.
The immunogenicity of rabies vaccines is commonly measured by serological testing, which includes measuring rabies virus-neutralising antibody titre levels in the serum. Apart from humoral immunity, cellular immunity measurements are also helpful in assessing the immunogenicity and efficacy of rabies vaccinations. Recently, there has been an increased emphasis on cellular immunity measurements against rabies in humans and animals.
View Article and Find Full Text PDFThe safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study.
Travel Med Infect Dis
January 2025
State Key Laboratory of Antibody Research &Development, Hebei Engineering Research Center of Antibody Medicine, North China Pharmaceutical Company New Drug Research and Development Co., Ltd., Shijiazhuang, 050015, China. Electronic address:
Background: The combination of passive immune agents (human rabies immune globulin (HRIG) and equine rabies antiserum (ERA)) with vaccines are effective measures for preventing the onset of rabies post exposure. However, ERA and HRIG have potential risks of serum allergic reactions and blood-transmitted infectious diseases. This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!